Dr. Goy Discusses Potential for Combination Therapies in MCL
Andre Goy, MD, discusses a few combinations that are being investigated for the treatment of patients with relapsed/refractory mantle cell lymphoma.
Andre Goy, MD, chief in the division of lymphoma, chairman and director at John Theurer Cancer Center, discusses a few combinations that are being investigated for the treatment of patients with mantle cell lymphoma (MCL).
Investigators are currently looking at combinations with novel agents such as venetoclax (Venclexta), which Goy says is going to be very important in the field of MCL. In addition, CAR T-cell therapy can also play a role in the treatment of patients with relapsed/refractory disease, he says.
Goy says his institution is part of the integration of these novel therapies that have made such an in the relapsed/refractory setting and the next step is determining how they can be brought to the frontline.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
